Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,424,128
  • Shares Outstanding, K 96,807
  • Annual Sales, $ 464,370 K
  • Annual Income, $ -139,670 K
  • 60-Month Beta 1.02
  • Price/Sales 16.64
  • Price/Cash Flow N/A
  • Price/Book 10.54
Trade ITCI with:

Options Overview Details

View History
  • Implied Volatility 45.00% ( -2.96%)
  • Historical Volatility 69.13%
  • IV Percentile 30%
  • IV Rank 13.26%
  • IV High 115.58% on 04/15/24
  • IV Low 34.20% on 09/14/23
  • Put/Call Vol Ratio 1.68
  • Today's Volume 2,561
  • Volume Avg (30-Day) 2,141
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 49,635
  • Open Int (30-Day) 42,084

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.33
  • Number of Estimates 6
  • High Estimate -0.24
  • Low Estimate -0.48
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +28.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.87 +12.73%
on 03/19/24
84.89 -15.18%
on 04/16/24
+6.63 (+10.14%)
since 03/18/24
3-Month
62.78 +14.69%
on 02/22/24
84.89 -15.18%
on 04/16/24
+6.86 (+10.53%)
since 01/18/24
52-Week
45.50 +58.24%
on 10/30/23
84.89 -15.18%
on 04/16/24
+9.61 (+15.40%)
since 04/18/23

Most Recent Stories

More News
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024

Stocks that traded heavily or had substantial price changes on Tuesday: UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall

IP : 35.26 (+0.57%)
NTRS : 81.41 (+0.22%)
PNC : 147.89 (+0.43%)
ABX.TO : 23.38 (+1.56%)
LYV : 89.64 (-2.37%)
UNH : 493.18 (+2.96%)
ITCI : 72.00 (-6.12%)
MS : 90.26 (+0.20%)
Intra-Cellular: Q4 Earnings Snapshot

Intra-Cellular: Q4 Earnings Snapshot

ITCI : 72.00 (-6.12%)
Intra-Cellular: Q3 Earnings Snapshot

Intra-Cellular: Q3 Earnings Snapshot

ITCI : 72.00 (-6.12%)
Intra-Cellular: Q2 Earnings Snapshot

Intra-Cellular: Q2 Earnings Snapshot

ITCI : 72.00 (-6.12%)
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

ITCI : 72.00 (-6.12%)
RCUS : 14.84 (unch)
ALLO : 3.46 (-1.42%)
OCUP : 1.6700 (-4.02%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 72.00 (-6.12%)
BCDA : 0.3770 (+2.42%)
Intra-Cellular: Q1 Earnings Snapshot

Intra-Cellular: Q1 Earnings Snapshot

ITCI : 72.00 (-6.12%)
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

ITCI : 72.00 (-6.12%)
ACAD : 17.07 (-0.70%)
AXSM : 65.72 (-5.72%)
APTX : 0.0960 (+3.11%)
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ITCI : 72.00 (-6.12%)
EXAS : 63.48 (+0.41%)
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

ITCI : 72.00 (-6.12%)
AXSM : 65.72 (-5.72%)
APTX : 0.0960 (+3.11%)
ANVS : 9.85 (+9.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 78.18
2nd Resistance Point 76.63
1st Resistance Point 74.31
Last Price 72.00
1st Support Level 70.44
2nd Support Level 68.89
3rd Support Level 66.58

See More

52-Week High 84.89
Last Price 72.00
Fibonacci 61.8% 69.84
Fibonacci 50% 65.19
Fibonacci 38.2% 60.55
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar